In 2016, Benetti et al. evaluated for the first time the effects of an SGLT2 inhibitor on the NLRP3 complex in the context of metabolic syndrome in an animal model of diet-induced obesity and insulin resistance87. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.